Webinars & Presentations Presentation: Enabling Scalable Cell Engineering Using Maxcyte Electroporation Platform

Presentation: Enabling Scalable Cell Engineering Using Maxcyte Electroporation Platform

This presentation was given during the Association of Biomolecular Resources Facilities Meeting (ABRF) March 2022.

Abstract:
MaxCyte is a U.S.-based global company leveraging its proprietary electroporation technology to accelerate the discovery, development, manufacturing and commercialization of next-generation medicines. During this presentation, we will explore how MaxCyte’s unique electroporation technology enables highly efficient, scalable engineering of cell lines and primary cells for a range of applications, including transient protein production, cell line development, and cell therapy manufacturing. We will showcase how our partners utilize the MaxCyte platform to shorten timelines, reduce cost, and de-risk cell engineering processes from concept to commercialization.

Watch Presentation

Presenter

Andrew Mancini

Andrew Mancini, Ph.D.

Field Application Scientist

Andrew Mancini is a Field Application Scientist at MaxCyte specializing in Cell and Gene Therapy. As a field-based scientist, Andrew works closely with MaxCyte’s partners around the world to develop novel cell engineering workflows for the development of cellular therapeutics. Prior to his time at MaxCyte, Andrew completed his PhD in Biomedical Sciences at the University of California, San Francisco and completed his postdoctoral training at Genentech in Molecular Oncology. He has broad range of experience and expertise that encompasses non-viral and viral engineering of primary immune cells, stem cells, and cell lines at both research and manufacturing scales.

Popular resources

Conditional-Deletion-of-Large-DNA-Fragment-in-iPSCs-by-ssODN-Mediated-Insertion-of-LoxP-Sites-without-Antibiotic-Selection-b 1
Scientific Brief
Conditional Deletion of Large DNA Fragment in iPSCs by ssODN-Mediated Insertion of LoxP Sites without Antibiotic Selection
Conditional-Deletion-of-Large-DNA-Fragment-in-iPSCs-by-ssODN-Mediated-Insertion-of-LoxP-Sites-without-Antibiotic-Selection-Fig-2 1
Scientific Brief
Gene Editing: Paving the Way for Accelerated Clinical Development of Adoptive Cell Therapies
Experimental-Design-hires 1
Scientific Brief
Conditional Deletion of Large DNA Fragment in iPSCs by ssODN-Mediated Insertion of LoxP Sites without Antibiotic Selection
View All Resources